A pilot FDA-approved clinical trial has demonstrated the safety and efficacy of the interoperable Artificial Pancreas System, a new smartphone-based application platform.
The iAPS app, which runs on an unlocked smartphone, is able to interface wirelessly with leading continuous glucose monitors, insulin pump devices and decision-making algorithms, according to researchers who presented results of the study in the journal Diabetes Technology & Therapeutics (DTT).
